Loading patent…
AssigneesChariot Innovations Ltd, Emory University, The University of Liverpool
InventorsLeopold TIENTCHEU, Schadrac AGBLA, Daniel KALMAN
Estimating the term…
The present invention is directed to a protein kinase inhibitor for use in the treatment of tuberculosis, by direct inhibition of the growth of a Mycobacterium tuberculosis complex species, and to corresponding methods of treating tuberculosis. More specifically, the invention relates to the use of protein tyrosine kinase inhibitors such as gefitinib, erlotinib, or imatinib for use in the treatment of tuberculosis, by direct inhibition of the growth of a Mycobacterium tuberculosis complex species, rather than through use in host-directed therapy. Also provided are methods of determining the ability of a protein tyrosine kinase inhibitor to inhibit the growth of a Mycobacterium tuberculosis complex species and methods of identifying a protein tyrosine kinase inhibitor as being potentially effective in the treatment of tuberculosis by direct inhibition of a Mycobacterium tuberculosis complex species.
1-49. (canceled)
A method of treating tuberculosis, the method comprising providing to a subject requiring such treatment an amount of a protein tyrosine kinase inhibitor that is:
(canceled)
(canceled)
(canceled)
A method of treating tuberculosis, the method comprising providing to a subject requiring such treatment an amount of gefitinib that is sufficient to directly inhibit the growth of a Mycobacterium tuberculosis complex species.
(canceled)
(canceled)
A method of treating tuberculosis, the method comprising providing to a subject requiring such treatment an amount of imatinib that is sufficient to directly inhibit the growth of a Mycobacterium tuberculosis complex species.
65-75. (canceled)
Dependencies are inferred from the claim text.